Arcutis Biotherapeutics' INTEGUMENT-PED Phase 3 Trial Of Roflumilast Cream 0.05%, In Children Ages 2 To 5 Years With Mild To Moderate Atopic Dermatitis Met Its Primary Endpoint And All Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics' INTEGUMENT-PED Phase 3 trial of Roflumilast Cream 0.05% in children aged 2 to 5 years with mild to moderate atopic dermatitis has met its primary endpoint and all secondary endpoints.
September 19, 2023 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcutis Biotherapeutics' successful Phase 3 trial results for Roflumilast Cream 0.05% could potentially boost the company's stock in the short term.
Successful clinical trial results are typically seen as positive news for pharmaceutical companies as they indicate progress towards regulatory approval and potential revenue generation. This news could therefore have a positive impact on Arcutis Biotherapeutics' stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100